Go Pro
→ Buy These Stocks Before August 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$80.68
+5.8%		$70.51
$24.85
▼
$80.97
$6.76B0.23794,004 shs845,826 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$36.85
-1.5%		$38.36
$11.53
▼
$43.73
$6.49B0.381.88 million shs1.25 million shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$102.24
+1.4%		$111.31
$63.23
▼
$130.00
$6.55B0.52756,210 shs556,260 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$20.77
+4.3%		$20.76
$12.99
▼
$25.59
$1.76B0.41.36 million shs1.19 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+5.75%+4.79%+14.95%+24.91%+215.65%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.47%-5.46%-3.79%+13.11%+213.35%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+1.36%+3.30%-12.33%+1.56%+56.91%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+4.27%+4.90%-6.82%+5.06%+34.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$80.68
+5.8%		$70.51
$24.85
▼
$80.97
$6.76B0.23794,004 shs845,826 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$36.85
-1.5%		$38.36
$11.53
▼
$43.73
$6.49B0.381.88 million shs1.25 million shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$102.24
+1.4%		$111.31
$63.23
▼
$130.00
$6.55B0.52756,210 shs556,260 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$20.77
+4.3%		$20.76
$12.99
▼
$25.59
$1.76B0.41.36 million shs1.19 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+5.75%+4.79%+14.95%+24.91%+215.65%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.47%-5.46%-3.79%+13.11%+213.35%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+1.36%+3.30%-12.33%+1.56%+56.91%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+4.27%+4.90%-6.82%+5.06%+34.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.183.10% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.85
Moderate Buy$49.4034.06% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3334.32% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.85
Moderate Buy$41.91101.78% Upside

Current Analyst Ratings Breakdown

Latest SNDX, CGON, COGT, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$52.00 ➝ $55.00
8/12/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $52.00
8/11/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$44.00 ➝ $40.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$123.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$137.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$148.00 ➝ $135.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,770.17N/AN/A$11.61 per share6.95
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$2.69 per shareN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M12.73$0.05 per share1,978.65($0.16) per share-639.00
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$172.35M10.68N/AN/A$0.17 per share122.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.16N/AN/AN/AN/A-84.47%-47.72%11/6/2026 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%11/3/2026 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$285.42M-$2.51N/AN/AN/A-87.52%-372.94%-39.11%11/2/2026 (Estimated)

Latest SNDX, CGON, COGT, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550-$0.52+$0.0350-$0.52$0.00 millionN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
8/4/2026Q2 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.4477-$0.55-$0.1023-$0.55$79.36 million$72.79 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.48
13.57
13.57
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
2.74
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
38.95
6.77
6.44

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80173.52 million162.09 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14064.93 million59.53 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11088.61 million84.36 millionOptionable

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971604
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-inc-nasdaqsndx-receives-average-rating-of-moderate-buy-from-analysts-2026-08-20/
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX
August 17 at 5:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-gsa-capital-partners-llp-purchases-new-position-in-syndax-pharmaceuticals-inc-sndx-2026-08-17/
JPMorgan Chase & Co. Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price
August 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957481
Syndax (SNDX) Q2 2026 Earnings Call Transcript
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/syndax-sndx-q2-2026-earnings-024523559.html
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-nasdaqsndx-given-new-4000-price-target-at-jpmorgan-chase-co-2026-08-11/
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-increases-stock-holdings-in-syndax-pharmaceuticals-inc-sndx-2026-08-09/
Q3 EPS Forecast for Syndax Pharmaceuticals Cut by Analyst
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949233
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
August 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/surging-revuforj-niktimvo-sales-narrowing-141819069.html
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-decreases-position-in-syndax-pharmaceuticals-inc-sndx-2026-08-08/
HC Wainwright Brokers Decrease Earnings Estimates for SNDX
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-brokers-decrease-earnings-estimates-for-sndx-2026-08-07/
What is HC Wainwright's Estimate for SNDX FY2029 Earnings?
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-sndx-fy2029-earnings-2026-08-06/
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339631/0/en/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931092-syndax-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation
Syndax Pharmaceuticals (SNDX) Q2 2026
August 5, 2026  |  247wallst.comhttps://247wallst.com/companies/sndx/earnings/
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-nasdaqsndx-shares-gap-down-on-disappointing-earnings-2026-08-05/
HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-lowered-expectations-for-syndax-pharmaceuticals-nasdaqsndx-stock-price-2026-08-05/
Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-grows-stake-in-syndax-pharmaceuticals-inc-sndx-2026-08-05/
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930518-syndax-pharmaceuticals-inc-sndx-q2-2026-earnings-call-transcript
Syndax: Q2 Earnings Snapshot
August 4, 2026  |  aol.comA
Syndax Pharmaceuticals Q2 Earnings Call Highlights
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-q2-earnings-call-highlights-2026-08-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$80.68 +4.39 (+5.75%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$80.72 +0.03 (+0.04%)
As of 08/19/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$36.85 -0.55 (-1.47%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$38.05 +1.20 (+3.26%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$102.24 +1.37 (+1.36%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$102.50 +0.26 (+0.25%)
As of 08/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$20.77 +0.85 (+4.27%)
As of 08/19/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas